Rajshekhar Chakraborty, MD

Articles by Rajshekhar Chakraborty, MD

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

Insights Across Hematologic Oncology at Columbia University

ByNicole Lamanna, MD,Rajshekhar Chakraborty, MD,Hua-Jay J Cherng, MD

March 16th 2026

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

Education, REMS certification, and long-term management are key barriers to the widespread adoption of bispecific antibodies in the community setting.

Dismantling Barriers to Early Adoption of Bispecifics in Multiple Myeloma

ByRajshekhar Chakraborty, MD

March 9th 2026

Education, REMS certification, and long-term management are key barriers to the widespread adoption of bispecific antibodies in the community setting.

Latest Updated Articles

Insights Across Hematologic Oncology at Columbia University
March 16th 2026
Dismantling Barriers to Early Adoption of Bispecifics in Multiple Myeloma
March 9th 2026

Trending on CancerNetwork

Daraxonrasib/Vopimetostat Yield Stunning Response Rate in MTAP-del Pancreatic Cancer

Melanoma Trials You May Have Missed at ASCO 2026

80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study